ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer
MADRID, Spain and CAMBRIDGE, Mass., April 08, 2024 -- Oryzon Genomics, S.A. , a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet...